Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) President Craig A. Wheeler sold 16,953 shares of Momenta Pharmaceuticals stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $16.94, for a total transaction of $287,183.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) traded up 2.20% during mid-day trading on Monday, hitting $16.25. 469,519 shares of the stock were exchanged. The stock’s 50 day moving average price is $16.80 and its 200-day moving average price is $15.69. Momenta Pharmaceuticals, Inc. has a 12-month low of $10.66 and a 12-month high of $19.90. The stock’s market capitalization is $1.20 billion.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share for the quarter, meeting the consensus estimate of ($0.50). Momenta Pharmaceuticals had a negative return on equity of 12.28% and a negative net margin of 39.35%. The business had revenue of $23.57 million for the quarter, compared to analysts’ expectations of $24.64 million. During the same period last year, the business earned ($0.31) EPS. The business’s revenue was down 10.8% on a year-over-year basis. On average, equities research analysts expect that Momenta Pharmaceuticals, Inc. will post ($1.20) EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Momenta Pharmaceuticals, Inc. (MNTA) President Craig A. Wheeler Sells 16,953 Shares” was originally reported by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.americanbankingnews.com/2017/08/14/momenta-pharmaceuticals-inc-mnta-president-craig-a-wheeler-sells-16953-shares.html.

MNTA has been the topic of a number of research reports. Stifel Nicolaus reissued a “buy” rating and issued a $26.00 price objective on shares of Momenta Pharmaceuticals in a research report on Thursday, August 3rd. BidaskClub raised shares of Momenta Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Barclays PLC lowered shares of Momenta Pharmaceuticals from an “overweight” rating to an “equal weight” rating and cut their price objective for the stock from $20.00 to $17.00 in a research report on Monday, May 22nd. Cowen and Company reissued a “hold” rating and issued a $15.00 price objective on shares of Momenta Pharmaceuticals in a research report on Wednesday, May 3rd. Finally, Aegis reissued a “hold” rating and issued a $17.00 price objective on shares of Momenta Pharmaceuticals in a research report on Wednesday, May 3rd. Two investment analysts have rated the stock with a sell rating, five have given a hold rating and two have given a buy rating to the company’s stock. Momenta Pharmaceuticals has a consensus rating of “Hold” and an average target price of $16.63.

Large investors have recently added to or reduced their stakes in the company. FMR LLC boosted its stake in Momenta Pharmaceuticals by 3.3% in the second quarter. FMR LLC now owns 11,125,193 shares of the biotechnology company’s stock worth $188,015,000 after buying an additional 351,743 shares during the last quarter. BlackRock Inc. boosted its stake in Momenta Pharmaceuticals by 7.1% in the second quarter. BlackRock Inc. now owns 9,400,485 shares of the biotechnology company’s stock worth $158,868,000 after buying an additional 626,415 shares during the last quarter. Vanguard Group Inc. boosted its stake in Momenta Pharmaceuticals by 4.9% in the second quarter. Vanguard Group Inc. now owns 6,243,767 shares of the biotechnology company’s stock worth $105,519,000 after buying an additional 290,090 shares during the last quarter. State Street Corp boosted its stake in Momenta Pharmaceuticals by 30.8% in the first quarter. State Street Corp now owns 2,455,449 shares of the biotechnology company’s stock worth $32,776,000 after buying an additional 577,504 shares during the last quarter. Finally, Palo Alto Investors LLC boosted its stake in Momenta Pharmaceuticals by 1.9% in the first quarter. Palo Alto Investors LLC now owns 1,759,376 shares of the biotechnology company’s stock worth $23,488,000 after buying an additional 31,996 shares during the last quarter. Institutional investors own 87.15% of the company’s stock.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.